Cargando…

Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis

The optimal concurrent chemotherapy regimen with radiotherapy for esophageal cancer is unknown. Here, we compared the survival outcomes and toxicity of definitive chemoradiotherapy with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin (DP) in patients with unresectable esophageal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Peng, Xi, Mian, Li, Qiao-Qiao, Hu, Yong-Hong, Guo, Xiaobo, Zhao, Lei, Liu, Hui, Liu, Shi-Liang, Luo, Li-Ling, Liu, Qing, Liu, Meng-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190128/ https://www.ncbi.nlm.nih.gov/pubmed/27183916 http://dx.doi.org/10.18632/oncotarget.9301

Ejemplares similares

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil
por: Tamaki, Yukihisa, et al.
Publicado: (2018)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019)

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma
por: Zhu, Yujia, et al.
Publicado: (2017)

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
por: Jiang, Hui, et al.
Publicado: (2023)

Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma
por: Jiang, Hui, et al.
Publicado: (2023)

Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
por: Zhang, Lu-Ning, et al.
Publicado: (2015)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis
por: Tao, Hao‐Yun, et al.
Publicado: (2021)

Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
por: Sato, Kotaro, et al.
Publicado: (2019)

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
por: Day, F L, et al.
Publicado: (2011)

Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma
por: Liu, Yong, et al.
Publicado: (2018)

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
por: Watanabe, Sho, et al.
Publicado: (2019)

Significance of concurrent use of weekly cisplatin in carbon‐ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score‐matched analysis
por: Okonogi, Noriyuki, et al.
Publicado: (2019)

Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma
por: Zampino, Maria G, et al.
Publicado: (2011)

Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer
por: Zhang, Yue, et al.
Publicado: (2023)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma
por: Zhu, Han-Ting, et al.
Publicado: (2017)

Complete remission in very advanced oral cancer by docetaxel, cisplatin, 5-fluorouracil based induction chemotherapy followed by concurrent chemoradiation
por: Chiang, Tien-En, et al.
Publicado: (2018)

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
por: Li, Chen, et al.
Publicado: (2021)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
por: Liu, Qi, et al.
Publicado: (2020)

Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
por: Yajima, Satoshi, et al.
Publicado: (2021)

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma
por: Zhang, Wen-Wen, et al.
Publicado: (2015)

Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016)

Hyperfractionated Radiotherapy with Concurrent Cisplatin/5-Fluorouracil for Locoregional Advanced Head and Neck Cancer: Analysis of 105 Consecutive Patients
por: Zaboli, David, et al.
Publicado: (2012)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
por: Luo, Yanrong, et al.
Publicado: (2022)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
por: Wang, Yan, et al.
Publicado: (2022)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
por: Yamaguchi, Takahisa, et al.
Publicado: (2023)

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial
por: Feng, Junfei, et al.
Publicado: (2016)

Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial
por: Yan, Pengwei, et al.
Publicado: (2020)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Liu, Tongxin, et al.
Publicado: (2018)

Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
por: Chen, Ruijuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_993jimhc14v80qpp7a1552c3pf